Cercar
01/01/2022
CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC)
Santos M.F., Almorox R.B., Solan L., Lopez O., Gallardo A., Garcia-Avila S., Esquirol A., Ferra C., Martin A., Garcia A., Perez E., Colorado M., Cortes M., Cabrero M., Gayoso J., Yañez L., Pascual M.J., Heras I.D.L., Diez J.L., Caballero M.D., Kwon M., Corral L.L.. CT-275 Incidence and Characteristics of Chronic GVHD in Haploidentical Stem-Cell Transplantation With Post-Transplantation Cyclophosfamide: Experience of the Spanish Group of Hematopoietic Transplantation and Cell Therapy (GETH-TC). Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01659-7. PMID:36164212. IF:(Q/D).
01/01/2022
CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study
Munir T., Moreno C., Owen C., Follows G., Benjamini O., Janssens A., Levin M.-D., Osterborg A., Robak T., Simkovic M., Stevens D., Voloshin S., Vorobyev V., Yagci M., Ysebaert L., Qi Q., Steele A., Schuier N., Baeten K., Caces D.B., Niemann C., Kater A.. CLL-106 First Prospective Data on Minimal Residual Disease Outcomes After Fixed-Duration Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for First-Line Treatment of CLL in Older Adult or Unfit Patients: The GLOW Study. Clinical Lymphoma Myeloma & Leukemia. 2022; 22DOI:10.1016/S2152-2650(22)01322-2. PMID:36163867. IF:(Q/D).
01/01/2022
First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial
Moreno C., Greil R., Demirkan F., Tedeschi A., Anz B., Larratt L., Simkovic M., Novak J., Strugov V., Gill D., Gribben J.G., Kwei K., Dai S., Hsu E., Dean J.P., Flinn I.W.. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. HAEMATOLOGICA. 2022; 107(9)DOI:10.3324/haematol.2021.279012. PMID:35021599. IF:10.100(Q1/2D).
01/01/2022
Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years (Leukemia, (2022), 36, 6, (1646-1653), 10.1038/s41375-022-01563-8)
Bazarbachi A., Boumendil A., Finel H., Khvedelidze I., Romejko-Jarosinska J., Tanase A., Akhtar S., Ben Othman T., Ma’koseh M., Afanasyev B., El-Cheikh J., Briones J., Gülbas Z., Hamladji R.-M., Elverdi T., Blaise D., Martínez C., Alma E., Halaburda K., Sousa A.B., Glass B., Robinson S., Montoto S., Sureda A.. Correction: The outcome of patients with Hodgkin lymphoma and early relapse after autologous stem cell transplant has improved in recent years (Leukemia, (2022), 36, 6, (1646-1653), 10.1038/s41375-022-01563-8). LEUKEMIA. 2022; 36(8)DOI:10.1038/s41375-022-01639-5. PMID:35840758. IF:11.400(Q1/1D).
01/01/2022
Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia
Barr P.M., Owen C., Robak T., Tedeschi A., Bairey O., Burger J.A., Hillmen P., Coutre S.E., Dearden C., Grosicki S., McCarthy H., Li J.-Y., Offner F., Moreno C., Zhou C., Hsu E., Szoke A., Kipps T.J., Ghia P.. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Advances. 2022; 6(11)DOI:10.1182/bloodadvances.2021006434. PMID:35377947. IF:7.500(Q1/2D).
01/01/2022
Medicina de precisión en leucemia linfática crónica: Análisis de coste-efectividad de nuevas combinaciones dirigidas
Meijide J.B.. Medicina de precisión en leucemia linfática crónica: Análisis de coste-efectividad de nuevas combinaciones dirigidas. Farmacia Hospitalaria. 2022; 46(3)DOI:10.7399/fh.13280. PMID:36183201. IF:(Q/D).
01/12/2025
Reticulocyte Count Interference at the Onset of Acute Myeloid Leukemia
Gutiérrez-Hernández, MD, Ramil, G, González-Alvarez, N, San-José, P. Reticulocyte Count Interference at the Onset of Acute Myeloid Leukemia. International Journal of Laboratory Hematology. 2025; 47(6)DOI:10.1111/ijlh.14545. PMID:40836604. IF:2.300(Q2/5D).
01/12/2025
Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy
Torrent, A, Morgades, M, Iacoboni, G, Reguera, JL, Kwon, M, Corral, LL, Hernani, R, Ortiz-Maldonado, V, Sanz, J, Gonzalez, ACC, Guerra, L, Pina, JMS, Mussetti, A, Garcia-Sancho, AM, Bastos-Oreiro, M, Delgado, J, Carpio, C, Sancho, JM, Perez-Martinez, A, Barba, P. Patient selection and treatment outcomes over time in patients with large B-cell lymphoma receiving car T-cell therapy. BONE MARROW TRANSPLANTATION. 2025; 60(12)DOI:10.1038/s41409-025-02722-y. PMID:41028300. IF:5.200(Q1/1D).
01/11/2025
Wolf's isotopic phenomenon in a patient with T-cell lymphoblastic lymphoma
Vilaseca, VG, Perez, ES, Fabrego, IE, Peral, IL, Prat, AM. Wolf's isotopic phenomenon in a patient with T-cell lymphoblastic lymphoma. MEDICINA CLINICA. 2025; 165(5)DOI:10.1016/j.medcli.2025.107073. PMID:40543401. IF:2.100(Q2/3D).
01/10/2025
Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single-Center Retrospective Analysis
Fasanella, MG, Mozos, A, Briones, J, Nomdedeu, JF, Novelli, S. Evaluation of Clinical Outcomes and Treatment Complications in Hairy Cell Leukemia: A Single-Center Retrospective Analysis. Cancer Reports. 2025; 8(10)DOI:10.1002/cnr2.70356. PMID:41031578. IF:(Q/D).
01/10/2025
Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study
Tolosa-Ridao, C, González, MB, Gómez, MA, Fox, L, Artigas, MDP, Santamaria, A, González, MDQ, Salinas, AS, Camacho, JMS, Alvaro, VI, Abdallahi-Lefdil, Z, Navascues, JC, Pardo, L, Fernández-Luis, S, Suárez, LPV, Villar, S, Beorlegui-Murillo, P, Esquirol, A, García, II, Ribes-Amorós, J, Lavilla, E, Lopez-Marín, J, Basalobre, P, Filaferro, S, Cedillo, A, Bento, L, Sureda, A, Salas, MQ. Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study. BRITISH JOURNAL OF HAEMATOLOGY. 2025; 207(4)DOI:10.1111/bjh.70068. PMID:40796522. IF:3.800(Q1/3D).
30/09/2025
Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma
Osuna-Gómez, R, López-Pardo, J, Mulet, M, Nomdedéu, J, Cantó, E, Ortin, R, Cayuela, AS, Ortiz, MA, Guinart-Cuadra, A, Vidal, S. Non-Competitive Binding of Isatuximab and Daratumumab to CD38: Implications for Targeted Therapy in Multiple Myeloma. Pharmaceutics. 2025; 17(10)DOI:10.3390/pharmaceutics17101278. PMID:41155915. IF:5.500(Q1/1D).
26/09/2025
Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation
Torrent-Rodríguez, A, Cascos, E, Garcés, VN, Pérez-López, E, Baile-González, M, Rodríguez, CM, Cascón, MJP, Luque, M, Esquirol, A, Calvo, CM, Peña-Muñoz, F, Fernando, IH, Ormtegi, IO, Marín, AJS, Fernández-Luis, S, Domínguez-García, JJ, Fernández, SV, Lorenzo, JLL, Girón, MFD, Pinedo, LG, García-Maño, L, González-Rodriguez, AP, Torrado, T, Filaferro, S, Basalobre, P, Ortí, G, Rovira, M, Chacón, MJ, Salas, MQ. Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation. Cancers. 2025; 17(19)DOI:10.3390/cancers17193128. PMID:41097656. IF:4.400(Q2/3D).
22/09/2025
Prevalence of Fms-Like Tyrosine Kinase 3 (FLT3) Mutations in Patients With Acute Myeloid Leukaemia: A Systematic Literature Review and Meta-Analysis
Lewis, JFM, Daver, NG, Robinson, NJ, Pandya, BJ, Pierre-Louis, B, Monir, S, Sierra, J. Prevalence of Fms-Like Tyrosine Kinase 3 (FLT3) Mutations in Patients With Acute Myeloid Leukaemia: A Systematic Literature Review and Meta-Analysis. Cancer Medicine. 2025; 14(18)DOI:10.1002/cam4.71205. PMID:40981231. IF:3.100(Q2/5D).
01/09/2025
Clinical characteristic and outcome of HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: A study of Infectious Disease Working Party of EBMT
Perruccio, K, Ward, KN, Tridello, G, Knelange, N, Zeiser, R, Franke, GN, Sirvent, A, Einsele, H, Vicent, MG, Navarro, JMF, Contentin, N, Collin, M, Martino, R, Gambella, M, Sengeloev, H, Passweg, J, Snowden, J, Nagler, A, Kulagin, A, Gabriel, M, Kröger, N, Cascon, MJP, Yeshurun, M, Güngör, T, Robin, C, Clark, A, Duarte, ML, Amor, AA, Itala-Remes, M, Mikulska, M, Styczynski, J, de la Camara, R, Ljungman, P, Averbuch, D, Cesaro, S. Clinical characteristic and outcome of HHV-6 encephalitis after allogeneic hematopoietic cell transplantation: A study of Infectious Disease Working Party of EBMT. BONE MARROW TRANSPLANTATION. 2025; 60(9)DOI:10.1038/s41409-025-02638-7. PMID:40461849. IF:5.200(Q1/1D).
01/09/2025
Characteristics of Long-Term Survivors in Multiple Myeloma: Exploring Factors for Cure After Extended Follow-Up
Fernandez, RA, Arroyo, A, Cedena, MT, Rosiñol, L, De la Rubia, J, Miqueleiz, S, González-Calle, V, de Arriba, F, Casado-Montero, F, Hernandez, MT, Mas, M, Fernandez-Abellan, P, Rodriguez-Otero, P, Calle, C, Abella, E, Ribas, P, Alegre, A, Bergua, JM, Ocio, E, De la Cruz, J, Mateos, MV, San-Miguel, J, Bladé, J, Lahuerta, JJ, Martinez-Lopez, J. Characteristics of Long-Term Survivors in Multiple Myeloma: Exploring Factors for Cure After Extended Follow-Up. Clinical Lymphoma Myeloma & Leukemia. 2025; 25DOI:. PMID:. IF:2.700(Q2/4D).
01/09/2025
Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study
Giménez, E, Cadenas, IG, Piñana, JL, Albert, E, Vázquez, L, Avendaño, A, Cabrero, M, Esquirol, A, Martino, R, López-Jiménez, J, Cuesta, MA, Humala, K, Villar, S, Rovira, M, Heras, I, Zudaire, T, Arroyo, I, Zabalza, A, Aguado, B, Solano, C, Navarro, D. Cytomegalovirus DNA Doubling Time for Early Identification of Clinically Significant Infection Episodes in Allogeneic Hematopoietic Stem Cell Transplant Recipients Undergoing Primary Letermovir Prophylaxis: A Multicenter Study. Transplant Infectious Disease. 2025; 27(5)DOI:10.1111/tid.70080. PMID:40674366. IF:2.600(Q1/1D).
01/08/2025
To proceed or delay? The dilemma of community-acquired respiratory viruses in adults and pediatrics before allogeneic stem cell transplantation and chimeric-antigen-receptor T-cell therapy
Pinana, JL, Martino, R, Cesaro, S, Averbuch, D, Lujgman, P. To proceed or delay? The dilemma of community-acquired respiratory viruses in adults and pediatrics before allogeneic stem cell transplantation and chimeric-antigen-receptor T-cell therapy. CURRENT OPINION IN INFECTIOUS DISEASES. 2025; 38(4)DOI:10.1097/QCO.0000000000001120. PMID:40471062. IF:4.000(Q1/2D).
25/07/2025
Co-infections during SARS-CoV-2 infection in hematologic patients and cell therapy recipients in the omicron era: a Spanish hematopoietic stem cell transplantation and cell therapy group study
Chorao, P, Avendano, A, Heras, I, Aiello, F, Micó-Cerdá, M, Bel, AA, Garcia-Gutierrez, V, Olave, MT, Gómez, MA, Espigado, I, Cuesta-Casas, MA, González-Santillana, C, Hernández-Rivas, JA, Roldán-Pérez, A, Labrador, J, Villalba, M, Vázquez, L, Vidal, CG, Martino, R, López-Jiménez, J, Cedillo, A, Solano, C, García-Cadenas, I, Piñana, JL. Co-infections during SARS-CoV-2 infection in hematologic patients and cell therapy recipients in the omicron era: a Spanish hematopoietic stem cell transplantation and cell therapy group study. BMC INFECTIOUS DISEASES. 2025; 25(1)DOI:10.1186/s12879-025-11302-w. PMID:40713537. IF:3.000(Q2/4D).
22/07/2025
Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis
Nath, K, Zhang, MJ, Bye, M, Abid, MB, Benjamin, C, Betts, B, Bhatt, NS, Bolanos, EA, Bolon, YT, Gadalla, SM, Grunwald, MR, Krem, MM, Lee, SJ, Marsh, SGE, Martino, R, Mehta, PA, Milano, F, Prestidge, T, Saultz, JN, Shaw, BE, Spellman, SR, Choe, H, Shaffer, BC. Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis. Blood Advances. 2025; 9(14)DOI:10.1182/bloodadvances.2024014858. PMID:40048743. IF:7.100(Q1/2D).
08/07/2025
Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study
Bento, L, Gutiérrez, A, Martinez, C, Verdet, MCO, Sorribes, M, Caballero, AC, Peña, M, Pérez, A, Jiménez-Ubieto, A, Medina, L, Bastos-Oreiro, M, Caldas-González, PF, Navarro, B, Salcedo, I, Abrisqueta, P, Español, I, Cornago, J, Martín-Moro, F, García, L, Gómez, P, Varela, MR, Puente, M, Zanabili, J, Zudaire, T, Zeberio, I, del Campo, R, González, L, González, P, Blázquez, C, Rovira, J, Sitges, M, Franch-Sarto, M, Cabero, A, Mussetti, A, Montoro, J, Sampol, A, Sureda, A, Caballero, D, García-Sancho, AM. Autologous stem cell transplantation for relapsed/refractory large B-cell lymphoma: a multicenter GETH-TC/GELTAMO study. Blood Advances. 2025; 9(13)DOI:10.1182/bloodadvances.2024015415. PMID:40163764. IF:7.100(Q1/2D).
01/07/2025
SGK1 repression by WT1 may confer a survival advantage to leukemic cells under stress conditions
Rubio, MA, Cisa-Wieczorek, S, Mozos, A, Castellet, H, Bussaglia, E, Carricondo, M, Hernández-Alvarez, MI, Sierra, J, Nomdedéu, JF. SGK1 repression by WT1 may confer a survival advantage to leukemic cells under stress conditions. ANNALS OF HEMATOLOGY. 2025; 104(7)DOI:10.1007/s00277-025-06458-z. PMID:40613901. IF:2.400(Q2/5D).
01/07/2025
Is t(11;14) Always aStandard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Trials
Moreno, DF, Oriol, A, de la Rubia, J, Hernández, MT, Iñigo, MB, Palomera, L, de Arriba, F, González, Y, Teruel, AI, Pardo, JL, de la Guía, AL, Sampol, A, Ríos-Tamayo, R, Sureda, A, Gutiérrez, NC, Calasanz, MJ, Ramos, MLM, Mateos, MV, San Miguel, J, Lahuerta, JJ, Bladé, J, Rosiñol, L. Is t(11;14) Always aStandard-Risk Cytogenetic Abnormality? Results From GEM05MENOS65 and GEM2012 PETHEMA/GEM Trials. Clinical Lymphoma Myeloma & Leukemia. 2025; 25(7)DOI:10.1016/j.clml.2025.01.014. PMID:39955256. IF:2.700(Q2/4D).
04/06/2025
Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party
Gagelmann, N, de Witte, M, Peczynski, C, Boreland, W, Broers, AEC, Jost, E, Kulagin, A, Esquirol, A, Sica, S, Kuball, J, Errico, G, Bethge, W, Maertens, J, Stölzel, F, Forcade, E, Collin, M, Parma, M, Choi, G, Kröger, N, Di Chio, MC, Finazzi, MC, Corral, LL, Rifón, J, Mussetti, A, Bloor, A, Ladetto, M, Schoemans, H, Penack, O, Moiseev, I, Peric, Z. Daratumumab for PRCA after HCT: study and practical considerations from the EBMT Transplant Complications Working Party. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01315-8. PMID:40467580. IF:11.600(Q1/1D).
01/06/2025
Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia
Jiménez-Vicente, C, Arribas, I, Pomares, H, Ramil, G, Castaño-Diez, S, Pérez-Valencia, AI, Sturla, AL, López-Guerra, M, Martinez-Roca, A, Zugasti, I, Guijarro, F, Cortés-Bullich, A, Merchán, B, Triguero, A, Monge, I, Tuca, A, Oñate, G, Garrido, A, Sierra, J, Arnan, M, Esteve, J, Díaz-Beyá, M. Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia. HAEMATOLOGICA. 2025; 110(6)DOI:10.3324/haematol.2024.286589. PMID:39844754. IF:10.100(Q1/2D).
14/05/2025
Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations
Jimenez-Vicente, C, Cardus, A, Castaño-Diez, S, Ramil, G, Garcia-Avila, S, Gomez-Perez, L, Esteban, D, Arribas, I, Sturla, AL, Lopez-Guerra, M, Martinez-Roca, A, Cortes-Bullich, A, Perez-Valencia, AI, Zugasti, I, Monge, I, Carcelero, E, Vall-Llovera, F, Vives, S, Sierra, J, Nomdedeu, J, Oñate, G, Garrido, A, Pratcorona, M, Pomares, H, Arnan, M, Guijarro, F, Diaz-Beya, M, Esteve, J. Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01298-6. PMID:40368916. IF:11.600(Q1/1D).
01/05/2025
Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance
Sobas, MA, Turki, AT, Ramiro, AV, Hernández-Sánchez, A, Elicegui, JM, González, T, Melchor, RA, Abáigar, M, Tur, L, Dall'Olio, D, Sträng, E, Tettero, JM, Castellani, G, Benner, A, Doehner, K, Thiede, C, Metzeler, KH, Haferlach, T, Damm, F, Ayala, R, Martínez-López, J, Mills, KI, Sierra, J, Lehmann, S, Della Porta, MG, Mayer, J, Reinhardt, D, Medina, RV, Schulze-Rath, R, Barbus, M, Hernández-Rivas, JM, Huntly, BJP, Ossenkoppele, G, Döhner, H, Bullinger, L. Outcomes with intensive treatment for acute myeloid leukemia: an analysis of two decades of data from the HARMONY Alliance. HAEMATOLOGICA. 2025; 110(5)DOI:10.3324/haematol.2024.285805. PMID:39506894. IF:10.100(Q1/2D).
01/04/2025
CNS manifestations in acute and chronic graft-versus-host disease
Lambert, N, Forte, F, El Moussaoui, M, Monseur, J, Raus, N, Polushin, A, Michonneau, D, Shultz, C, Hogan, WJ, Balaguer-Roselló, A, Gil-Perotín, S, Brijs, J, Chauvet, P, Gavriilaki, M, Carre, M, Dulamea, AO, Chalandon, Y, Salmenniemi, U, Duminuco, A, Ram, R, García-Cadenas, I, Porto, G, Nguyen, S, Smallbone, P, González-Vicent, M, Santoro, JD, Willems, E, Baron, F, Servais, S, Beguin, Y, Maquet, P, CNS GvHD Study Grp. CNS manifestations in acute and chronic graft-versus-host disease. BRAIN. 2025; 148(4)DOI:10.1093/brain/awae340. PMID:39442000. IF:11.700(Q1/1D).
01/04/2025
The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide
Spyridonidis, A, Labopin, M, Savani, BP, Kulagin, A, Blaise, D, Broers, AEC, Sica, S, Raiola, AM, Vydra, J, Choi, G, Rovira, M, Kwon, M, Sanz, J, Itäla-Remes, M, von dem Borne, P, Esquirol, A, Koc, Y, Brissot, E, Nagler, A, Mohty, M, Ciceri, F. The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide. BONE MARROW TRANSPLANTATION. 2025; 60(4)DOI:10.1038/s41409-025-02514-4. PMID:39910175. IF:5.200(Q1/1D).
21/03/2025
Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
Jiménez-Vicente, C, Esteve, J, Baile-González, M, Pérez-López, E, Calvo, CM, Aparicio, C, Ormategi, IO, Esquirol, A, Peña-Muñoz, F, Fernandez-Luis, S, Fernando, IH, González-Rodríguez, AP, López-García, A, López-Lorenzo, JL, Torrado, T, Marín, AJS, Fleytas, CA, García, L, Villar, S, Filaferro, S, Balsalobre, P, Cascón, MJP, Salas, MQ. Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC). Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-025-01223-x. PMID:40118819. IF:11.600(Q1/1D).
05/03/2025
Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection
Navarro, S, Moukheiber, C, Sancho, SI, Guillén, MR, de Cerio, ALD, Sanges, C, Tanaka, T, Arnould, S, Briones, J, Dolstra, H, Hudecek, M, Choudhary, R, Schapitz, I, Juan, ME, Worel, N, Ammar, D, Luu, M, Mueller, M, Schroeder, B, Negre, H, Franz, P. Optimizing CAR-T treatment: A T2EVOLVE guide to raw and starting material selection. MOLECULAR THERAPY. 2025; 33(3)DOI:10.1016/j.ymthe.2024.11.017. PMID:39533710. IF:12.000(Q1/1D).
01/03/2025
Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC
Escamilla-Gómez, V, Gutiérrez, VG, Alcalde-Mellado, P, Astibia-Mahillo, B, Chinea-Rodriguez, A, López-Corral, L, Acera-Gómez, M, Ochando, MKT, Borrego, AB, Pinedo, LG, Ripa, TZ, Vicent, MG, Benzaquén, A, García, II, Cantó, PA, Montoro, J, Martín-Domínguez, FM, Orti, G, Valcárcel, D, Benitez-Carabante, MI, Diaz-de-Heredia, C, Cañamero, E, Ferrá, C, García-Cadenas, I, Redondo, S, Sisinni, L, Perez-Martínez, A, Mussetti, A, Garcia-Mañó, L, Palomo-Moraleda, MD, González-Sierra, PA, Jurado, M, Perez-Simon, JA. Ruxolitinib in acute and chronic graft-versus-host disease: real life long-term experience in a multi-center study for adult and pediatric patients, on behalf of the GETH-TC. BONE MARROW TRANSPLANTATION. 2025; 60(3)DOI:10.1038/s41409-024-02483-0. PMID:39663471. IF:5.200(Q1/1D).
01/02/2025
Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features
Sierro-Martinez, B, Escamilla-Gomez, V, Perez-Ortega, L, Guijarro-Albaladejo, B, Hernandez-Diaz, P, de la Rosa-garrido, M, Lara-Chica, M, Rodriguez-Gil, A, Reguera-Ortega, JL, Sanoja-Flores, L, Arribas-Arribas, B, Montiel-Aguilera, MA, Carmona, G, Robles, MJ, Caballero-Velazquez, T, Briones, J, Einsele, H, Hudecek, M, Perez-Simon, JA, Garcia-Guerrero, E. Next-generation BCMA-targeted chimeric antigen receptor CARTemis-1: the impact of manufacturing procedure on CAR T-cell features. CELLULAR ONCOLOGY. 2025; 48(1)DOI:10.1007/s13402-024-00984-0. PMID:39192092. IF:4.800(Q1/1D).
11/01/2025
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group
Oñate, G, Garrido, A, Arnan, M, Pomares, H, Alonso, E, Tormo, M, Diaz-Beya, M, Vives, S, Zamora, L, Sampol, A, Coll, R, Salamero, O, Cervera, M, Garcia, A, Vall-Llovera, F, Garcia-Avila, S, Bargay, J, Ortin, X, Iranzo, E, Guijarro, F, Pratcorona, M, Nomdedeu, JF, Esteve, J, Sierra, J. Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group. Blood Cancer Journal. 2025; 15(1)DOI:10.1038/s41408-024-01205-5. PMID:39799145. IF:11.600(Q1/1D).
07/01/2025
Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care
Salas, MQ, Solano, MT, González, MB, Gómez, MA, Fox, L, Artigas, MDP, Santamaría, A, González, MDQ, Salinas, AS, Camacho, JMS, Alvaro, VI, Abdallahi-Lefdil, Z, Navascues, JC, Pardo, L, Fernández-Luis, S, Suárez, LPV, Villar, S, Beorlegui-Murillo, P, Esquirol, A, García, II, González, SR, Mussetti, A, Lavilla, E, Lopez-Marín, J, Filaferro, S, Cedillo, A, Bento, L, Sureda, A. Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care. Frontiers in Immunology. 2025; 15DOI:10.3389/fimmu.2024.1512154. PMID:39840039. IF:5.900(Q1/2D).
01/01/2025
Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials
González-Gil, C, Morgades, M, Lopes, T, Fuster-Tormo, F, Montesinos, P, Barba, P, Díaz-Beya, M, Hermosín, L, Maluquer, C, González-Campos, J, Bernal, T, Arriaga, MS, Zamora, L, Pratcorona, M, Martino, R, Larrayoz, MJ, Artola, T, Torrent, A, Vall-llovera, F, Tormo, M, Gil, C, Novo, A, Martínez-Sánchez, P, Ribera, J, Queipo, MP, González-Martínez, T, Cabrero, M, Cladera, A, Cervera, J, Orfao, A, Ribera, JM, Genescà, E. Contribution of copy number to improve risk stratification of adult T-cell acute lymphoblastic leukemia patients enrolled in measurable residual disease-oriented trials. HAEMATOLOGICA. 2025; 110(1)DOI:10.3324/haematol.2024.285416. PMID:39113657. IF:10.100(Q1/2D).
01/01/2025
Alder-Reilly Leukocyte Inclusions in a patient with Mucopolysaccharidosis Type VII
Bhambi-Blanco, I, González-Alvarez, N, San-José, P. Alder-Reilly Leukocyte Inclusions in a patient with Mucopolysaccharidosis Type VII. ANNALES DE BIOLOGIE CLINIQUE. 2025; 83(-1)DOI:10.1684/abc.2025.1953. PMID:39953854. IF:0.400(Q4/10D).
01/01/2025
Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain
de Larrea, CF, Loscertales, J, Cabañas, V, Freiria, C, Blanchard, MJ, Askari, E, Perez, ML, Abril, L, Pardo, JL, Pinzón, S, Gálvez, JD, Amer, N, Páyer, AR, Sánchez, RG, Alcalá, MM, Capote, FJ, Moreno, D, Bolumburu, C, Rubio-Azpeitia, E, Sanz, RG. Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain. Therapeutic Advances in Hematology. 2025; 16DOI:10.1177/20406207251379670. PMID:. IF:3.100(Q2/4D).
21/11/2024
Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
Döhner, H, Dinardo, CD, Appelbaum, FR, Craddock, C, Dombret, H, Ebert, BL, Fenaux, P, Godley, LA, Hasserjian, RP, Larson, RA, Levine, RL, Miyazaki, Y, Niederwieser, D, Ossenkoppele, G, Röllig, C, Sierra, J, Stein, EM, Tallman, MS, Tien, HF, Wang, JX, Wierzbowska, A, Wei, AH, Löwenberg, B. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. BLOOD. 2024; 144(21)DOI:10.1182/blood.2024025409. PMID:39133932. IF:23.100(Q1/1D).
12/11/2024
Cardiac events after allo-HCT in patients with acute myeloid leukemia
Salas, MQ, Cascos, E, López-García, A, Pérez, E, Baile-González, M, Rodríguez, CM, Cascón, MJP, Luque, M, Esquirol, A, Fernando, IH, Peña-Muñóz, F, Ormtegi, IO, Marín, AJS, Fernández-Luis, S, Dominguez-García, JJ, Fernández, SV, Girón, MFD, Pinedo, LG, Garcia, L, González-Rodriguez, AP, Torrado, T, Filaferro, S, Cedillo, A, Orti, G, Chacón, MJ. Cardiac events after allo-HCT in patients with acute myeloid leukemia. Blood Advances. 2024; 8(21)DOI:10.1182/bloodadvances.2024013535. PMID:39178345. IF:7.100(Q1/2D).